目的 探討復(fù)方雙花口服液聯(lián)合美洛西林舒巴坦鈉治療小兒急性化膿性扁桃體炎的臨床療效。方法 選取2019年1月—2020年12月在天津市泰達(dá)醫(yī)院兒科住院治療的86例小兒急性化膿性扁桃體炎患兒，根據(jù)隨機(jī)數(shù)字法將86例急性化膿性扁桃體炎患兒分為對(duì)照組和治療組，每組各43例。對(duì)照組患兒靜脈滴注注射用美洛西林鈉舒巴坦鈉，75 mg/kg，使用5%葡萄糖或0.9%氯化鈉溶液100 mL或150 mL稀釋，8 h/次。治療組患兒在對(duì)照組的基礎(chǔ)上口服復(fù)方雙花口服液，4～7歲，10 mL/次，4次/d，7歲以上，20 mL/次，3次/d。兩組患兒連續(xù)用藥5 d。觀察兩組患兒的臨床療效，比較兩組患兒臨床癥狀緩解時(shí)間、白細(xì)胞介素6（IL-6）、白細(xì)胞介素8（IL-8）、腫瘤壞死因子-α（TNF-α）、C反應(yīng)蛋白（CRP）。結(jié)果 治療后，治療組患兒總有效率是97.67%，顯著高于對(duì)照組的79.07%（P<0.05）。治療過(guò)程中，治療組患兒發(fā)熱、咽痛、膿性分泌物、扁桃體腫大等臨床癥狀緩解時(shí)間均顯著短于對(duì)照組（P<0.05）。治療后，兩組患兒血清IL-6、IL-8、TNF-α、CRP水平均顯著降低（P<0.05）；治療后，治療組血清炎性因子水平低于對(duì)照組（P<0.05）。結(jié)論 復(fù)方雙花口服液聯(lián)合美洛西林舒巴坦鈉治療急性化膿性扁桃體炎具有較好的臨床療效，能有效改善患兒臨床癥狀，降低炎性反應(yīng)，值得臨床推廣使用。

Objective To investigate the curative effect of Compound Shuanghua Oral Liquid combined with mezlocillin sodium and sulbactam sodium in treatment of acute suppurative tonsillitis in children. Methods A total of 86 children with acute suppurative tonsillitis hospitalized in tianjin TEDA Hospital from January 2019 to December 2020 were selected. According to the random number method, 86 children with acute suppurative tonsillitis were divided into the control group and the treatment group, with 43 cases in each group. Patients in the control group were iv administered with Mezlocillin Sodium and Sulbactam Sodium for injection, 75 mg/kg, diluted with 5% glucose or 0.9% sodium chloride solution 100 mL or 150 mL, 8 h/time. Patients in the treatment group were po administered with Compound Shuanghua Oral Liquid on the basis of the control group, 4-7 years old, 10 mL/time, 4 times daily, 7 years old and over, 20 mL/time, 3 times daily. Patients in two groups were treated for 5 d. After treatment, the clinical efficacy was evaluated, and clinical symptom remission time, IL-6, IL-8, TNF-α, and CRP were compared between two groups. Results After treatment, the total effective rate in the treatment group was 97.67%, which was significantly higher than 79.07% in the control group (P < 0.05). During the treatment, the improvement time of fever, sore throat, purulent secretion, and enlarged tonsil in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the serum levels of IL-6, IL-8, TNF-α and CRP in two groups were significantly decreased (P < 0.05). After treatment, the levels of serum inflammatory factors in the treatment group were lower than those in the control group (P < 0.05). Conclusion Compound Shuanghua Oral Liquid combined with mezlocillin sodium and sulbactam sodium has good clinical effect in treatment of acute suppurative tonsillitis in children, and can effectively improve the clinical symptoms of children and reduce the inflammatory response, which is worthy of clinical promotion and usage.

R985;R987